These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 27343423

  • 1. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N, Li Y, Xu T, Li L, Kwong JS, Du H, Ren K, Li Q, Li J, Sun X, Li S, Tian H.
    Int J Cardiol; 2016 Sep 15; 219():293-300. PubMed ID: 27343423
    [Abstract] [Full Text] [Related]

  • 2. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.
    BMJ; 2012 Jan 10; 344():d7771. PubMed ID: 22236411
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S.
    J Diabetes Res; 2015 Jan 10; 2015():157201. PubMed ID: 25688373
    [Abstract] [Full Text] [Related]

  • 6. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
    Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X, Huang Y, Shi X, Xue R, Fu X, Wang S.
    Am J Clin Nutr; 2023 Sep 10; 118(3):614-626. PubMed ID: 37661106
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
    Shamim MA, Patil AN, Amin U, Roy T, Tiwari K, Husain N, Kumar J, Chenchula S, Rao P, Ganesh V, Varthya SB, Singh S, Shukla R, Rastogi A, Gandhi AP, Satapathy P, Sah R, Padhi BK, Dwivedi P, Khunti K.
    Diabetes Obes Metab; 2024 Oct 10; 26(10):4302-4317. PubMed ID: 39044306
    [Abstract] [Full Text] [Related]

  • 8. Exenatide as a novel weight loss modality in patients without diabetes.
    Moreno JL, Willett KC, Desilets AR.
    Ann Pharmacother; 2012 Dec 10; 46(12):1700-6. PubMed ID: 23191935
    [Abstract] [Full Text] [Related]

  • 9. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
    Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH.
    PLoS One; 2015 Dec 10; 10(6):e0126769. PubMed ID: 26121478
    [Abstract] [Full Text] [Related]

  • 10. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
    Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Ji L, Zhan S.
    Endocrine; 2015 Apr 10; 48(3):794-803. PubMed ID: 25115635
    [Abstract] [Full Text] [Related]

  • 11. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.
    Zheng H, Liu M, Li S, Shi Q, Zhang S, Zhou Y, Su N.
    Front Endocrinol (Lausanne); 2021 Apr 10; 12():706914. PubMed ID: 34484120
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA.
    ; 2018 09 10. PubMed ID: 30354042
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
    Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY.
    BMJ Open; 2023 Mar 07; 13(3):e061807. PubMed ID: 36882248
    [Abstract] [Full Text] [Related]

  • 15. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
    Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH.
    Diabetes Obes Metab; 2017 Feb 07; 19(2):162-171. PubMed ID: 27717222
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.
    Diabetes Obes Metab; 2013 Aug 07; 15(8):737-49. PubMed ID: 23433305
    [Abstract] [Full Text] [Related]

  • 17. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S.
    Diabetes Res Clin Pract; 2015 Oct 07; 110(1):26-37. PubMed ID: 26358202
    [Abstract] [Full Text] [Related]

  • 18. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
    Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, Wang L, Yang H, Gong F.
    Horm Metab Res; 2022 Jul 07; 54(7):458-471. PubMed ID: 35512849
    [Abstract] [Full Text] [Related]

  • 19. Green tea for weight loss and weight maintenance in overweight or obese adults.
    Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E.
    Cochrane Database Syst Rev; 2012 Dec 12; 12(12):CD008650. PubMed ID: 23235664
    [Abstract] [Full Text] [Related]

  • 20. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P, Civantos S, Vega B, Pavón I, Guijarro G, Monereo S.
    Obes Surg; 2015 Mar 12; 25(3):575-8. PubMed ID: 25589020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.